Galectin Therapeutics Inc.

GALT Nasdaq SEC CIK 1133416
Follow Galectin Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.5M +56.9% vs same quarter last year
EPS, diluted −$0.04 +69.2% vs same quarter last year
Operating cash flow −$2.3M +36.1% vs same quarter last year
Operating income −$3.4M +19.8% vs same quarter last year
Net income by quarter
−$12M
−$9.6M
−$7.5M
−$8.2M
−$5.5M
−$5M
−$9.1M
−$3.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$30.8M
FY24−$47M
FY23−$41.1M
FY22−$38.8M
FY21−$30.5M
FY20−$23.5M
FY19−$13.3M
FY18−$13.9M
FY17−$16.2M
FY16−$21.4M
FY15−$20M
FY14−$15.8M
FY13−$12.1M
FY12−$9.7M
FY11−$10.9M
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15−$17M
FY14−$12.4M
FY13−$7.5M
FY12−$7.5M
FY11−$5.7M